Table 3.
No | Low | Medium | High | |
---|---|---|---|---|
Level | 0.0085 ± 0.092 | 1.1 ± 0.340 | 1.9 ± 0.750,1 | 2.6 ± 0.530,1,2 |
cvxEDA | ||||
Phasic, µS | 1.2 ± 2.8 | 1.3 ± 2.5 | 2 ± 3.60 | 1.2 ± 22 |
Tonic, µS | 7.8 ± 8.4 | 9.9 ± 9.7 | 6.8 ± 8.51 | 8.3 ± 7.6 |
dphEDA | −0.065 ± 0.18 | 0.14 ± 0.240 | 0.22 ± 0.30 | 0.27 ± 0.30,1 |
Phasic driver (a.u.) | 2.4 ± 5.2 | 3.3 ± 3.7 | 4.9 ± 4.70 | 4 ± 40 |
sparsEDA | ||||
Phasic, µS | 0.31 ± 0.96 | 0.67 ± 3.1 | 0.66 ± 1.20 | 0.6 ± 0.89 |
Tonic, µS | 8.8 ± 7.3 | 11 ± 8.7 | 8.2 ± 6.7 | 8.9 ± 7.1 |
dphEDA | −0.081 ± 0.17 | 0.19 ± 0.680 | 0.22 ± 0.270 | 0.27 ± 0.290 |
Phasic driver (a.u.) | 0.1 ± 0.59 | 0.57 ± 2.10 | 0.94 ± 1.60 | 1.1 ± 1.40,1 |
Spectral | ||||
TVSymp | 0.78 ± 0.62 | 0.88 ± 0.67 | 1.2 ± 0.890,1 | 1.4 ± 0.820,1 |
MTVSymp | 0.13 ± 0.18 | 0.21 ± 0.25 | 0.33 ± 0.330,1 | 0.4 ± 0.340,1 |
“No”: 0 ≤ VAS < 1; “low”: 1 ≤ VAS < 4; “medium”: 4 ≤ VAS < 7; “high”: 7 ≤ VAS ≤ 10. Superscript numbers denote significant differences to the given pain sensation levels. cvxEDA, convex optimization of electrodermal activity; dphEDA, derivative of the phasic component of electrodermal activity; MTVSymp, modified time-varying index of electrodermal activity; sparsEDA, sparse deconvolution of electrodermal activity; TVSymp, time-varying index of electrodermal activity; VAS, visual analog scale. Repeated-measures analysis using ANOVA or Dunn’s test for normal or non-normal distributed data, respectively.